Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T Nia JulianFebruary 8, 2022
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Nia JulianJanuary 11, 2022
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer Nia JulianAugust 20, 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline Nia JulianAugust 18, 2021
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 Nia JulianJuly 27, 2021
Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder Nia JulianJuly 12, 2021
Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Nia JulianJuly 6, 2021
Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis Nia JulianJune 30, 2021
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism Nia JulianJune 28, 2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors Nia JulianJune 17, 2021
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial Nia JulianJune 15, 2021
Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma Nia JulianApril 7, 2021
FDA Approves G1 Therapeutics' Cosela to Prevent Chemo Damage in Lung Cancer Nia JulianFebruary 15, 2021
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer Nia JulianFebruary 11, 2021
CARISMA THERAPEUTICS COMPLETES SERIES B FUNDING FOR $47 MILLION TO ADVANCE DEVELOPMENT OF NOVEL CAR-MACROPHAGE IMMUNOTHERAPIES Nia JulianJanuary 7, 2021
Redwood City-based Seer's stock nearly tripled in IPO, valuing company at over $3B Nia JulianDecember 8, 2020
